Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing featuring AtaCor Medical
Background
Extravascular implantable cardioverter-defibrillators (EV-ICDs) are being developed to overcome limitations of current implantable cardioverter-defibrillators (ICDs). The AtaCor parasternal EV-ICD system uses an extravascular lead along the left parasternum to deliver defibrillation and pacing therapy from outside the heart.
Objective
This pilot study analysis evaluates implant success, acute performance, and 30-day safety of the parasternal EV-ICD system.
Methods
Patients with a class I or IIa indication for ICD therapy were implanted with the parasternal EV-ICD system and underwent acute defibrillation testing. End points included acute defibrillation success and 30-day freedom from major complications.
